ライフサイエンスコーパス: AYA

1 AYA communication and decision making can be challenging

2 AYA decision-making involvement is associated with impor

3 AYA tumors also exhibit more driver gene fusions that ar

4 A total of 1226 AYA patients (63.6%) had a documented discussion about p

5 Additionally, data were collected from 152 AYA SOT recipients demonstrating a substantial gap in ho

6 Among 1929 AYA patients with a mean (SD) age at cancer diagnosis of

7 The analytic population included 1929 AYA decedents, of whom 1049 (54.4%) were female; 227 (11

8 There were 415 (34.3%) AYA and 795 (65.7%) parents.

9 sequencing data from 21 children (<15y), 32 AYA (15-39y), and 60 adults (>39y) with ACC, and retaine

10 On subset analysis of 349 AYA patients with tumors of the stomach and small intest

11 enrollment and time to treatment among 1,358 AYA patients with cancer (age 15 to 39 years) identified

12 84 [12%] Black, and 522 [73%] White) and 369 AYA patients with AML from the Alliance for Clinical Tri

13 In this study of 717 pediatric and 369 AYA patients with AML, the ACS10 score was associated wi

14 This study included 392 AYA and 5373 OA patients diagnosed with GISTs (207 [52.8

15 This retrospective cohort study of 392 AYA patients and 5373 older adult (OA) patients in the S

16 We included 782 454 AYA living with HIV (698 066 [89.2%] women) with 1 428 1

17 OPE) study, a population-based cohort of 523 AYA patients with cancer, ages 15 to 39 years at diagnos

18 tients enrolled in the study (88.9%) with 53 AYA-parent dyads.

19 y data and electronic health records for 663 AYA patients with either stage I to III cancer and evide

20 s is a retrospective case-only study of 8860 AYA breast cancer cases diagnosed from 1997 to 2006 usin

21 A total of 291 899 AYA patients (median age, 33 years [IQR, 28-37 years]; 1

22 On subset analysis of 91 AYA patients with metastatic disease, operative manageme

23 eness among research ethics committees about AYA-independent consent) required further refinement to

24 any survivors of adolescent and young adult (AYA) cancer, yet data on this population's fertility per

25 neoplasms after adolescent and young adult (AYA) cancer.

26 in survivors of adolescent and young adult (AYA) cancers are poorly characterized.

27 ,00 survivors of adolescent and young adult (AYA) cancers in the United States, a number that is expe

28 Survivors of adolescent and young adult (AYA) cancers, defined as individuals diagnosed with a pr

29 Adolescent and young adult (AYA) enrollment in cancer clinical trials (CCT) is subop

30 s in the care of adolescent and young adult (AYA) germ cell tumors (GCTs) are needed for one of the m

31 Adolescent and young adult (AYA) oncology patients are unique in many aspects of the

32 Adolescent and young adult (AYA) patients need additional support, while they experi

33 lts, the care of adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) po

34 Adolescent and young adult (AYA) patients with advanced cancer often die in hospital

35 quality care for adolescent and young adult (AYA) patients with cancer and survivors requires an unde

36 Because adolescent and young adult (AYA) patients with cancer have experienced variable impr

37 in the US among adolescent and young adult (AYA) patients with cancer.

38 cer diagnosis in adolescent and young adult (AYA) patients with cancer.

39 ls who work with adolescent and young adult (AYA) patients with cancer.

40 y was to compare adolescent and young adult (AYA) pediatric cancer survivors and peers without a hist

41 outcomes of the adolescent and young adult (AYA) population with gastrointestinal stromal tumors (GI

42 t groups for the adolescent and young adult (AYA) population with HL.

43 T-cell therapy in pediatric and young adult (AYA) relapsed or refractory B-cell acute lymphoblastic l

44 e, especially in adolescent and young adult (AYA) renal transplant recipients.

45 graft failure in adolescent and young adult (AYA) solid organ transplant (SOT) recipients.

46 is important to adolescent and young adult (AYA) survivors of cancer.

47 er time among adolescents and younger adult (AYA) patients aged 12 to 39 years with cancer near the e

48 iagnosed in adolescence and young adulthood (AYA) in the US.

49 As adolescence and young adulthood (AYA) is a time when fully syndromal BD often emerges, an

50 ancer during adolescent and young adulthood (AYA) may alter the development and psychological traject

51 nbinary (TGNB) adolescents and young adults (AYA) designated female at birth (DFAB) experience chest

52 ortant role of adolescents and young adults (AYA) in accelerating and sustaining coronavirus disease

53 ACC in adolescents and young adults (AYA) is rarely due to germline TP53, IGF2, PRKAR1A and M

54 in children, adolescents, and young adults (AYA) to treat relapsed/refractory B-cell acute lymphobla

55 preferences of adolescents and young adults (AYA) with advanced heart disease.

56 tional care of adolescents and young adults (AYA) with allergy and/or asthma.

57 Adolescents and young adults (AYA) with asthma and allergies have unexpectedly high mo

58 Adolescents and young adults (AYA) with asthma and allergies need to develop the knowl

59 Adolescents and young adults (AYA) with cancer have been designated as a vulnerable po

60 e on cancer in adolescents and young adults (AYA; aged 15-24 years) living with HIV is scarce.

61 It is unclear how cancer affects AYA income over time compared with the general populatio

62 of the excess number of neoplasms across all AYA groups investigated.

63 ed outcomes is experienced equitably for all AYA patients.

64 We identified all AYA in Ontario, Canada age 15-21 years when diagnosed wi

65 The survey was sent to all AYA RI Network members (n = 143) and quantitative and th

66 and OA (>/=40 years old) patients and among AYA patients stratified by operative management.

67 9 years, with the 10 deadliest cancers among AYA patients who received a diagnosis from January 1, 20

68 er-related cognitive impairment (CRCI) among AYA survivors.

69 adult transplant centers, age, and LFU among AYA renal transplant recipients.

70 ion, transition readiness and outcomes among AYA patients with IBD being cared for at pediatric cente

71 icantly higher mean levels of symptoms among AYA cancer survivors.

72 aiser Permanente Southern California, and an AYA cancer support community (lacunaloft.org).

73 identified who reported having cancer as an AYA (374 respondents), receiving a first-time cancer dia

74 Eligible caregivers cared for an AYA living with advanced cancer or one who had died with

75 ecting and sharing data from every child and AYA can enable greater understanding of pediatric cancer

76 sing substantial unmet needs in children and AYA patients diagnosed with certain pediatric cancers.

77 ategies to optimize outcomes in children and AYA receiving CD19 CAR T cells.

78 itators were similar across institutions and AYA program types.

79 ore was associated with EFS in pediatric and AYA patients when treated with a standard induction regi

80 rtise in the following three critical areas: AYA-specific medical knowledge; care delivery specific t

81 , unique domains were identified, as well as AYA-specific manifestations of existing domains.

82 life; (d) enrolling the family in assisting AYA to undertake self-management; and (e) encouraging AY

83 in adolescents and young adults with BD (BD(AYA)) and at high risk for BD (HR-BD(AYA)) that is relat

84 al review, fMRI studies of BD(AYA) and HR-BD(AYA) are discussed, and a preliminary neurodevelopmental

85 BD (BD(AYA)) and at high risk for BD (HR-BD(AYA)) that is related to acute mood states and trait vul

86 and prevent the onset of mood episodes in BD(AYA), are outlined.

87 In this critical review, fMRI studies of BD(AYA) and HR-BD(AYA) are discussed, and a preliminary neu

88 The majority of costs are borne by AYA cancer survivors themselves in the form of lost prod

89 LFU is a critical problem faced by AYA renal transplant recipients, and institution transfe

90 tization analysis on germline DNA of 1,507 C-AYA patients with solid tumors, we show 12% of these pat

91 n children, adolescents, and young adults (C-AYA).

92 for ACC, especially in the Childhood-AYA (C-AYA) population.

93 factor for ACC, especially in the Childhood-AYA (C-AYA) population.

94 ss sectional survey was developed by the COG AYA Oncology Discipline Committee Responsible Investigat

95 This collaborative AYA approach pioneering successfully in GCT could serve

96 Across 33 common AYA cancers, AYAs and children had high 5-year relative

97 (GCTs) are needed for one of the most common AYA cancers for which treatment has not significantly ch

98 CONCLUSION AYA cancer survivors did not differ from peers in psycho

99 after adjusting for demographic covariates, AYA cancer survivors had higher odds of lifetime psychia

100 val varied across races for the 10 deadliest AYA cancers.

101 ed on size, presence or absence of dedicated AYA programs, and proximity and relationship between ped

102 Top surgery in TGNB DFAB AYA is associated with low complication rates.

103 In addition to the newly diagnosed AYA patient, there are growing numbers of AYA survivors

104 Results Recently diagnosed AYA patients with cancer had significantly worse physica

105 the 12- to 24-month period after diagnosis, AYA patients may benefit from supportive care interventi

106 A diagnosis of cancer during AYA, defined as ages 15 to 39 years.

107 (4) Effective AYA programs require provider and system flexibility and

108 dertake self-management; and (e) encouraging AYA to let their friends know about their allergies and

109 ed, multidisciplinary approach, (c) ensuring AYA fully understand their condition and have resources

110 For example, AYA survivors are often treated in disparate settings (p

111 dult Health Outcomes and Patient Experience (AYA HOPE) Comorbidity Index, which includes conditions t

112 dult Health Outcomes and Patient Experience (AYA HOPE) study, a population-based cohort of 523 AYA pa

113 r Registry (CCR) was used to identify female AYA cancer survivors diagnosed from January 2000 to Dece

114 inform the reproductive counseling of female AYA cancer survivors.

115 Few AYA patients had palliative goals documented in the init

116 crowdsourcing, or youth advisory boards) for AYA engagement in and education about research as well a

117 ndividualization of the approach to care for AYA patients and their caregivers.

118 cilitators of effective transfer of care for AYA SOT recipients; (2) to actively explore strategies a

119 aft recommendations on transitional care for AYA with allergy and/or asthma and their parents.

120 actice and challenges on transition care for AYA with asthma and allergies, including the impact of t

121 s to support effective transitional care for AYA with asthma and allergies.

122 ment of health care professionals caring for AYA patients with cancer.

123 We highlight the unique considerations for AYA cancer survivors, identify gaps in knowledge for fut

124 Five-year survival rates are lowest for AYA women, and only a few studies have examined the impa

125 symptoms later in life was only observed for AYA cancer survivors.

126 implementing improved consent processes for AYA research participation at the organizational, commun

127 y of using a pediatric treatment regimen for AYA patients with newly diagnosed ALL administered by ad

128 ndations on operating a clinical service for AYA, which include the following: (a) starting transitio

129 ider how best to approach future therapy for AYA patients.

130 e focus of the next stage of ALL therapy for AYA should not only involve novel treatment approaches b

131 -based guideline on effective transition for AYA with asthma and allergies was published by EAACI.

132 PCS but not MCS scores were worse for AYA patients diagnosed with cancers with poorer prognose

133 n of insignificant forward transmission from AYA pose a risk of inadvertent reinvigoration of local t

134 , non-conductive HCN4-channel subunit (hHCN4-AYA).

135 However, AYA have not been prioritized as a key population in the

136 the prognostic value of TERT alterations in AYA melanoma, we investigated the association of TERT pr

137 matic case presentations-may be amplified in AYA.

138 Breast cancer in AYA women has a worse prognosis than in older women.

139 cidence rates for the most common cancers in AYA living with HIV, and we assessed associations betwee

140 understanding the biology of late effects in AYA cancer survivors and to developing personalized inte

141 w of clinically actionable genetic events in AYA tumors.

142 nt is associated with improved OS and GSS in AYA patients, including those with metastatic disease.

143 FP is extraordinarily important in AYA oncology and can be addressed in many ways: experime

144 recent studies have reported improvements in AYA cancer survival overall.

145 We studied cancer incidence in AYA living with HIV in South Africa between 2004 and 201

146 ulation and may predict clinical outcomes in AYA melanoma.

147 ted with low clinical trial participation in AYA patients with cancer.

148 th new insights into disease pathogenesis in AYA ALL and the availability of disease-specific kinase

149 ical oncology community, and including PC in AYA cancer care delivery can help attain that goal.

150 cal effectiveness of transition processes in AYA cancer survivors.

151 d other socioeconomic factors on survival in AYA women.

152 To identify current trends in AYA care, we examined patterns of clinical trial partici

153 cancers were the most common cancer types in AYA living with HIV in South Africa, and their incidence

154 ticenter retrospective cohort study included AYA patients (aged 12-39 years) with cancer who died bet

155 Oncology frontline protocols, which included AYA patients from 9 different trials that enrolled patie

156 owever, PC is inconsistently integrated into AYA oncology care, and access to PC programs is not equi

157 rs have high potential to improve site-level AYA enrollment.

158 ients diagnosed with GISTs (207 [52.8%] male AYA patients, 2767 [51.5%] male OA patients, 277 [70.7%]

159 European HCP managing AYA with allergies and/or asthma were invited to partici

160 Although many AYA patients with cancer died in their preferred locatio

161 dities, including subsequent neoplasms, many AYA survivors do not engage in health behaviors at the r

162 PATIENTS AND METHODS AYA cancer survivors (n = 167) and controls (n = 170), r

163 Compared with the OA patients, more AYA patients had small-intestine GISTs (139 [35.5%] vs 1

164 Most AYA participants stated a preference to discuss adverse

165 Most AYA patients received at least 1 form of medically inten

166 Although most AYA patients with cancer return to work after cancer, tr

167 rsons born preterm, 54.6% were alive with no AYA HOPE comorbidities at the end of follow-up.

168 und gaps in MOUD access between AYAs and non-AYA populations in addition to differences in MOUD acces

169 cancer treatment is reported by 30%-100% of AYA cancer survivors.

170 4.8% of the children (P = 0.004) and 6.2% of AYA (P < 0.0001), all-female participants, harbored germ

171 Multivariable analysis of AYA patients found that nonoperative management was asso

172 y, pharmacology, and psychosocial aspects of AYA patients with ALL, highlighting our current approach

173 derstood about the unique disease biology of AYA ALL, targeted therapeutic approaches may offer promi

174 hes on the understanding of tumor biology of AYA CNS tumors is emphasized.

175 and Kaiser Permanente Southern California of AYA patients with cancer who were 12 to 39 years of age

176 ssionals to support the transitional care of AYA with allergy and/or asthma.

177 15, compared the baseline characteristics of AYA (13-39 years old) and OA (>/=40 years old) patients

178 To describe a large cohort of AYA patients with GISTs and investigate the effect of su

179 Studies in large international cohorts of AYA cancer survivors have now shown that the burden of l

180 nd competency in application and delivery of AYA-specific practical knowledge.

181 Yet efforts of AYA patients with cancer and survivors to mature are oft

182 The majority of AYA (72.3%) and parents (81.9%) were female.

183 medical, educational and vocational needs of AYA in the developmentally appropriate way.

184 l interventions consider the unique needs of AYA survivors by developmental stage and across multiple

185 ed AYA patient, there are growing numbers of AYA survivors of childhood cancer who present with conce

186 The growing population of AYA cancer survivors makes it imperative that these effo

187 vidence regarding the increased potential of AYA to transmit SARS-CoV-2 that, to date, has received l

188 rch infrastructure (35%) and the presence of AYA champions (33%).

189 The greatest proportion of AYA participants (24 of 53 participants [45.3%]) indicat

190 This will ensure better representation of AYA patients in research studies.

191 tudy was conducted among a diverse sample of AYA patients with cancer ages 15 to 39 years.

192 racteristics in a population-based sample of AYA patients with cancer.

193 This cohort study of AYA patients suggests that stage at diagnosis and surviv

194 In this cross-sectional study of AYA patients who died of cancer, palliative goals were r

195 dult treatment approaches and subanalyses of AYA patients will help guide harmonization of treatment.

196 aracterized in this population, subgroups of AYA survivors appear to be at risk for experiencing CRCI

197 Although the survival of AYA patients is inferior to younger children, growing ev

198 A total of 5,673 2-year survivors of AYA cancer and 57,617 comparison patients were included,

199 The cohort included 6,778 survivors of AYA cancer and 87,737 persons without a history of cance

200 Survivors of AYA cancer are at increased risk for developing CVD.

201 Survivors of AYA cancer are at substantially increased risk of advers

202 g comorbidities is increased in survivors of AYA cancer compared with the general population.

203 ve cohort study included 2-year survivors of AYA cancer diagnosed between age 15 and 39 years at Kais

204 Survivors of AYA cancer had a 2- to 3-fold increased risk for cardiom

205 In this cohort study, survivors of AYA cancer had high rates of perceiving increased infert

206 Forty percent of survivors of AYA cancer had multiple (>= 2) comorbidities at 10 years

207 ss-sectional estimates revealed survivors of AYA cancer had the highest prevalence of lifetime psychi

208 m mental health trajectories of survivors of AYA cancer into later adulthood have not been explored.

209 In this cohort study, survivors of AYA cancer reported significantly worse mental health tr

210 retrospective cohort of 2-year survivors of AYA cancer who were diagnosed between the ages of 15 to

211 burden of this cancer in future survivors of AYA cancer.

212 The health care needs of survivors of AYA cancers are particularly complicated given the often

213 ractical toolbox for effective transition of AYA with asthma and allergies have been published.

214 bsequent primary neoplasm after each type of AYA cancer.

215 primary neoplasms after each of 16 types of AYA cancer.

216 bsequent primary neoplasms after 16 types of AYA cancer: breast; cervical; testicular; Hodgkin lympho

217 national hospital-based oncology database on AYA patients, aged 15 to 39 years, with the 10 deadliest

218 icaid expansion has had a moderate effect on AYA outcomes.

219 the Alliance for Clinical Trials in Oncology AYA non-HSCT cohort, the low ACS10 score group had signi

220 as a model for impactful research for other AYA cancer types.

221 Overall, AYA survivors appear to be at elevated risk of emotional

222 opics and targeted healthcare professionals, AYA, parents/carers, schools, workplace and wider commun

223 lanning, and psychosocial programs promoting AYA resilience) are all associated with improved patient

224 linical priorities include improved provider-AYA communication regarding SH, standardization of SH me

225 cisions on behalf of their AYA, representing AYA-parent decision-making discordance (chi2 = 11.7; P =

226 ch as simplifying medication regimes, seeing AYA on their own or producing transition reports.

227 development of prognostic assays to stratify AYA melanoma patients according to clinical risk.

228 network play an essential role in supporting AYA in this process.

229 OC evolve may guide clinicians in supporting AYA patients in making end-of-life decisions.

230 adolescent and young adult cancer survivors (AYA [diagnosed at ages 15-39 years]) with those of women

231 As), but little is known about the care that AYA patients with cancer receive at the end of life (EOL

232 ols and techniques are needed to ensure that AYA survivors move seamlessly from acute cancer care to

233 This study found that AYA patients are more likely to undergo surgical managem

234 ger children, growing evidence suggests that AYA patients have improved outcomes, with disease-free s

235 The AYA population (age 15-39 years) is diverse in terms of

236 Themes were consistent across the AYA age range and participant type.

237 on and trial eligibility criteria across the AYA spectrum, enabling more rapid progress.

238 number of issues uniquely experienced by the AYA population that are critical for health care profess

239 ms undergo dynamic maturational changes, the AYA epoch is implicated as a critical period in the neur

240 reproductive potential are critical for the AYA population at the time of diagnosis.

241 iers to building therapeutic alliance in the AYA advanced cancer population from the perspective of a

242 of how to build therapeutic alliance in the AYA advanced cancer population, which may guide clinicia

243 ately 80% of all malignant CNS tumors in the AYA age group, with the most common types observed being

244 en age, institution transfer, and LFU in the AYA population are still needed.

245 momas and medulloblastomas also occur in the AYA population but are seen less frequently.

246 d risks for long-term adverse effects in the AYA population remain understudied.

247 f the unique distribution of diseases in the AYA population with cancer and further understanding of

248 ncers manifest themselves differently in the AYA population, both in terms of biology and treatment r

249 erview of HL epidemiology and biology in the AYA population, this review will cover frontline pediatr

250 well as other CNS tumor types common in the AYA population.

251 nt, these regimens are well tolerated in the AYA population.

252 ocols significantly improves outcomes in the AYA population.

253 c trials to include the full spectrum of the AYA population.

254 ent of an adult mindset are hallmarks of the AYA population; these transitions heighten the intrinsic

255 pported recommendation was checking that the AYA is knowledgeable and compliant with their prescribed

256 ing the therapeutic alliance specific to the AYA population, including managing discordant needs betw

257 bile technologies for communication with the AYA.

258 to enhance the care and outcomes within the AYA population.

259 shared medical decisions on behalf of their AYA, representing AYA-parent decision-making discordance

260 rominence of lung cancer after each of these AYA cancers indicates the need for further work aimed at

261 y component of successful treatment of these AYA patients.

262 This AYA approach has been fostered by The Malignant Germ Cel

263 aches, an evolving holistic care approach to AYA HL will result in enhanced understanding of unique c

264 isions that limit public health attention to AYA and are driven by the assumption of insignificant fo

265 Overall, 2598 births to AYA cancer survivors (mean [SD] maternal age, 31 [5] yea

266 Births to AYA cancer survivors had a significantly increased preva

267 Live births to AYA cancer survivors may have an increased risk of prete

268 014 to identify postdiagnosis live births to AYA survivors (n = 2598).

269 Shared barriers and facilitators to AYA CCT enrollment exist across the landscape of cancer

270 ored site level barriers and facilitators to AYA enrollment on CCTs and the efficacy of interventions

271 ot confident and involving peers in training AYA patients; (c) identifying and managing psychological

272 In most cancer types, AYA tumors show lower mutation burden and less genome in

273 At the 24-month follow-up, AYA patients still had significantly lower PCS scores (4

274 using reminders; (b) focusing on areas where AYA are not confident and involving peers in training AY

275 [51.5%] male OA patients, 277 [70.7%] white AYA patients, and 3661 [68.1%] white OA patients).

276 rimary oncologist, address these issues with AYA patients.

277 for health care professionals working within AYA oncology (AYAO) to understand.